Studies on Shokyo, Kanzo, and Keihi in Kakkonto Medicine on Prostaglandin E2 Production in Lipopolysaccharide-Treated Human Gingival Fibroblasts. (13th October 2016)

• Record Type: Journal Article
• Authors: Ara, Toshiaki; Sogawa, Norio
• Other Names: Hsu Fong-Fu Academic Editor.
• Is Part Of: International scholarly research notices. Volume 2016(2016)
• Publication Date: 2016-10-13
• Subjects: Medical sciences -- Periodicals; Life sciences -- Periodicals; Medicine -- Periodicals; Science -- Periodicals; Biomedical Technology; Biological Science Disciplines; Medicine; Life sciences; Medical sciences; Medicine; Science; Periodical; Periodicals; Fulltext; Internet Resources; Periodicals; Electronic journals
• DOI: 10.1155/2016/9351787
• Languages: English
• ISSNs: 2356-7872

Abstract

Abstract : We previously demonstrated that a kampo medicine, kakkonto, decreases lipopolysaccharide- (LPS-) induced prostaglandin E2 (PGE2 ) production by human gingival fibroblasts. In this study, we examined the herbs constituting kakkonto that exhibit this effect. Shokyo strongly and concentration dependently and kanzo and keihi moderately decreased LPS-induced PGE2 production. Shokyo did not alter cyclooxygenase-2 (COX-2) activity, cytosolic phospholipase A2 (cPLA2 ), annexin 1 and COX-2 expression, and LPS-induced extracellular signal-regulated kinase (ERK) phosphorylation. Kanzo inhibited COX-2 activity but increased annexin 1 and COX-2 expression and did not alter LPS-induced ERK phosphorylation. Keihi inhibited COX-2 activity and LPS-induced ERK phosphorylation but slightly increased COX-2 expression and did not alter cPLA2 and annexin 1 expression. These results suggest that the mechanism of shokyo is through the inhibition of cPLA2 activity, and that of kanzo and keihi is through the inhibition of COX-2 activity and indirect inhibition of cPLA2 activity. Therefore, it is possible that shokyo and kakkonto are clinically useful for the improvement of inflammatory responses.